D-0844-2020 Class III Terminated

Recalled by The Harvard Drug Group — Livonia, MI

FDA drug recall D-0844-2020 was initiated by The Harvard Drug Group on Dec 13, 2019 and is designated Class III. Reason for recall: Failed Dissolution Specifications: High out of specification result observed at stability studies. The recall status is terminated (terminated Nov 4, 2020). Affected quantity: 246 Cartons.

Recall details

Product Type
Drugs
Report Date
Feb 26, 2020
Initiation Date
Dec 13, 2019
Termination Date
Nov 4, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
246 Cartons

Product description

Memantine Hydrochloride Extended-release Capsules, 28mg, packaged in 100-count Unit Dose Cartons , Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202 United States; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 48152 USA, NDC 0904-6735-61

Reason for recall

Failed Dissolution Specifications: High out of specification result observed at stability studies.

Distribution pattern

U.S.A. Nationwide

Code information

Lot# M02465D

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0844-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0844-2020. Report a data issue: hello@regdatalab.com.